Feedback

Browsing by L

Use an asterisk (*) for partial word searches (e.g. pemph*)

114 results found.

1.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

2.
Ordering Recommendation:  

Refer to aruplab.com/bodyfluids for clinical indications and interpretive information.

3.
Ordering Recommendation:  

Do not use to detect myocardial injury. Troponin I (0090613) and Troponin T (0098803) are the recommended tests for diagnosis and management of acute coronary syndrome. In rare cases, this test may be used to evaluate elevated lactate dehydrogenase associated with non-cardiac muscle injury.

4.
Ordering Recommendation:  

Assess a variety of pathological conditions, primarily in hematology and oncology.

5.
Ordering Recommendation:  

When considering pyruvic acid testing, this is the preferred test.  This test reports concentrations for lactate, pyruvate, and the L:P ratio on the same specimen.

6.
7.
8.
Ordering Recommendation:  

Diagnose and monitor lactic acidosis in hypoxic and metabolic diseases.

9.
Ordering Recommendation:  

Do not use to diagnose inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS); may be used for monitoring IBD activity.

10.
Ordering Recommendation:  

Detect lactase deficiency.

11.
Ordering Recommendation:  

Quantify and determine clonality of free lambda light chains (Bence Jones protein) in urine. Monitor treatment response if gammopathy is known to be lambda.

12.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

13.
14.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

15.
16.
Ordering Recommendation:  

Assess cardiovascular disease risk and guide therapy.

17.
Ordering Recommendation:  

Differentiate LDL particles with respect to size to identify individuals with phenotype A (large LDL particles) or B (small LDL particles); considered as a nontraditional CVD risk marker.

18.
Ordering Recommendation:  

Determine if the Le(a) (LE1) antigen is expressed on the patient's red blood cells. To ensure accurate results, order concurrently with LEB Antigen Typing - Patient (2007723).

19.
Ordering Recommendation:  

Recommended for routine testing for lead exposure in pediatric populations. Confirm elevated results with Lead, Blood (Venous) (0020098).

20.
Ordering Recommendation:  

Recommended for routine testing for lead exposure. For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016).

21.
Ordering Recommendation:  

Recommended for the assessment of industrial lead exposure in adults and provides exposure guidance in accordance with OSHA regulations. To assess lead exposure in a non-occupational setting, Lead, Blood (Venous) (0020098) is preferred.

22.
Ordering Recommendation:  

May be useful in the assessment of chronic lead exposure or in monitoring chelation therapy. For routine testing of lead exposure, Lead, Blood (Venous) (0020098) is preferred. For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016).

23.
Ordering Recommendation:  

Not recommended for the routine assessment of lead toxicity.

24.
Ordering Recommendation:  

May be useful in the assessment of chronic lead exposure or in monitoring chelation therapy. For routine testing of lead exposure, Lead, Blood (Venous) (0020098) is preferred. For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016).

25.
Ordering Recommendation:  

Determine if the Le(b) (LE2) antigen is expressed on the patient's red blood cells. To ensure accurate results, order concurrently with LEA Antigen Typing - Patient (2007733).

26.
Ordering Recommendation:  

Therapeutic monitoring and evaluating full elimination of the drug (eg, toxicity, pregnancy).

27.
Ordering Recommendation:  

Provide retrospective evidence of suspected Legionella pneumophila infection.

28.
Ordering Recommendation:  

May be useful when acute legionellosis is suspected; however, Legionella pneumophila Antigen, Urine (0070322) is preferred.

29.
Ordering Recommendation:  

Provide retrospective evidence of suspected Legionella pneumophila infection.

30.
Ordering Recommendation:  

May be useful when acute legionellosis is suspected; however, Legionella pneumophila Antigen, Urine (0070322) is preferred.

31.
Ordering Recommendation:  

Provide retrospective evidence of suspected Legionella pneumophila infection.

32.
Ordering Recommendation:  

Use for the rapid identification of L. pneumophila; sensitivity is dependent on patient population and specimen type. Molecular testing is generally preferred; refer to Legionella Species by Qualitative PCR (2010125).

33.
Ordering Recommendation:  

Detect Legionella species.

34.
Ordering Recommendation:  

Gold standard test; detects L. pneumophila and other Legionella species in clinical specimens.

35.
Ordering Recommendation:  

Acceptable diagnostic and predictive test for Legius syndrome for symptomatic individuals who test negative for NF1 gene variants.

36.
Ordering Recommendation:  

Preferred test to confirm Legius syndrome for symptomatic individuals who test negative for NF1 gene variants.

37.
Ordering Recommendation:  

Aid in the diagnosis of leishmaniasis.

38.
39.
Ordering Recommendation:  

Aids in the detection of acute leptospirosis.

40.
Ordering Recommendation:  

May provide definitive diagnosis, but sensitivity is low and culture may take several weeks to yield result.

41.
Ordering Recommendation:  

Aid in diagnosis of leucine-rich glioma inactivated 1 protein (LGI1) antibody disorders associated with limbic encephalitis, hyponatremia, and myoclonic movements. Disorders are rarely associated with tumors.
Aid in diagnosis of contactin associated protein 2 (CASPR2) antibody disorders associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome.
Use to manage antibody-positive (LGI1 or CASPR2) individual following immunotherapy and/or plasmapheresis

42.
Ordering Recommendation:  

Aid in diagnosis of leucine-rich glioma inactivated 1 protein (LGI1) antibody disorders associated with limbic encephalitis, hyponatremia, and myoclonic movements. Disorders are rarely associated with tumors. Use to manage antibody-positive (LGI1) individual following immunotherapy and/or plasmapheresis.

43.
Ordering Recommendation:  

Aid in evaluation of hematopoietic neoplasms (ie, leukemia, lymphoma). Monitor therapy in patients with established diagnosis of hematopoietic neoplasms.

44.
Ordering Recommendation:  

Aids in the diagnosis of type I and II leukocyte adhesion deficiency. Panel measures CD11b, CD15, and CD18 on neutrophils.

45.
Ordering Recommendation:  

Aid in differential diagnosis of neutrophilia, including chronic myeloid leukemia (CML) and leukemoid reaction.

46.
47.
Ordering Recommendation:  

Appropriate initial test for Li-Fraumeni  syndrome (LFS). Should not be used to detect somatic TP53 variants associated with malignancy. Not recommended for patients with a hematologic malignancy and/or who have undergone allogeneic stem cell transplantation.

48.
Ordering Recommendation:  

Most comprehensive test for Li-Fraumeni syndrome (LFS). Should not be used to detect somatic TP53 variants associated with malignancy. Not recommended for patients with a hematologic malignancy and/or who have undergone allogeneic stem cell transplantation.

49.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

50.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

51.
52.
Ordering Recommendation:  

Refer to aruplab.com/bodyfluids for clinical indications and interpretive information.

53.
54.
Ordering Recommendation:  

Assess cardiovascular disease risk and guide therapy.

55.
Ordering Recommendation:  

Assess cardiovascular disease risk and guide therapy.

56.
Ordering Recommendation:  

Carrier screening or diagnostic testing for lipoamide dehydrogenase deficiency for individuals of Ashkenazi Jewish descent.

57.
Ordering Recommendation:  

Use in appropriate high-risk patients (eg, type 2 diabetes mellitus) in whom LDL particle number is being used to guide therapy. Not recommended for cardiovascular disease risk assessment in most individuals; preferred test is Lipid Panel (0020421).

58.
Ordering Recommendation:  

Use in appropriate high-risk patients (eg, type 2 diabetes mellitus) in whom LDL particle number is being used to guide therapy. Not recommended for cardiovascular disease risk assessment in most individuals; preferred test is Lipid Panel (0020421).

59.
Ordering Recommendation:  

Not recommended for cardiovascular risk assessment in asymptomatic adults. May aid in CVD risk stratification in specific populations.

60.
Ordering Recommendation:  

Determine the Fredrickson classification of individuals with hyperlipoproteinemia. Most useful for identifying the Type III phenotype.

61.
62.
63.
Ordering Recommendation:  

Monitor patient adherence and exposure.

64.
Ordering Recommendation:  

Determine if the c (RH4) antigen is expressed on the patient's red blood cells. To determine if the patient is heterozygous or homozygous for the c antigen, C Antigen Typing - Patient (2007933) should also be ordered.

65.
Ordering Recommendation:  

Determine if the e (RH5) antigen is expressed on the patient's red blood cells. To determine if the patient is heterozygous or homozygous for the e antigen, E Antigen Typing - Patient (2007941) should also be ordered.

66.
Ordering Recommendation:  

Determine if the little s (MNS4) antigen is expressed on the patient's red blood cells. To determine if the patient is heterozygous or homozygous for the s antigen, S Antigen Typing - Patient (2007739) should also be ordered.

67.
Ordering Recommendation:  

Use to evaluate for autoimmune hepatitis of unknown etiology. Use in combination with Liver-Kidney Microsome - 1 Antibody, IgG.

68.
Ordering Recommendation:  

Noninvasive assessment of liver fibrosis in patients with chronic viral hepatitis B or C (with or without HIV coinfection) and in patients with hepatic steatosis. Test can be performed only if the patient has a FibroScan score. Result based on both a panel of serum biomarkers (FibroMeter) and the FibroScan Vibration Controlled Transient Elastography (VCTE), a noninvasive, diagnostic ultrasound-based test that measures liver fibrosis.

69.
Ordering Recommendation:  

Noninvasive, serum surrogate marker test for assessment of liver fibrosis in patients with chronic viral hepatitis.

70.
Ordering Recommendation:  

Only intended for use in patients with non-alcoholic liver disease (NAFLD); results may be inaccurate in patients with other etiologies of liver disease.

71.
Ordering Recommendation:  

Differential evaluation of autoimmune liver disease of unknown etiology, especially autoimmune hepatitis (AIH) of childhood onset. Use in combination with Liver Cytosolic Antigen Type 1 (LC-1) Antibody, IgG (2010711) when evaluating for AIH-2.

72.
Ordering Recommendation:  

Differential evaluation of autoimmune liver disease of unknown etiology, especially autoimmune hepatitis (AIH) of childhood onset. Use in combination with Liver Cytosolic Antigen Type 1 (LC-1) Antibody, IgG (2010711) when evaluating for AIH-2.

73.
Ordering Recommendation:  

Confirm suspected laminopathy caused by LMNA deletions/duplications including Emery-Dreifuss muscular dystrophy type 2, Limb-girdle muscular dystrophy 1B or dilated cardiomyopathy.

74.
Ordering Recommendation:  

Confirm suspected laminopathy caused by LMNA mutations including Hutchinson-Gilford progreria, Emery-Dreifuss muscular dystrophy type 2, Limb-girdle muscular dystrophy 1B, Charcot-Marie-Tooth 2B1, Dunnigan type familial partial lipodystrophy, mandibulo-acral dysplasia, atypical Werner syndrome, restrictive dermopathy or dilated cardiomyopathy.

75.
Ordering Recommendation:  

Confirm clinical diagnosis of Loeys-Dietz syndrome.

76.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

77.
Ordering Recommendation:  

Useful for general screening to assess drug abuse. Positive drug screen results are confirmed.

78.
79.
Ordering Recommendation:  

Screening panel detects EGFR mutations (pyrosequencing), ALK and ROS1 fusion proteins (IHC).

80.
Ordering Recommendation:  

Screening panel detects EGFR and KRAS mutations (pyrosequencing), ALK and ROS1 fusion proteins (IHC).

81.
Ordering Recommendation:  

Use for unexplained prolonged PTT or for patients with a significant probability of having antiphospholipid syndrome (APS).  For APS, order with Cardiolipin Antibodies, IgG and IgM (0099344) and Beta-2 Glycoprotein 1 Antibodies, IgG and IgM (anti-beta[2]GP1) (0050321).

82.
Ordering Recommendation:  

Recommended for the evaluation of systemic lupus erythematosus (SLE).

83.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

84.
85.
Ordering Recommendation:  

Test is intended for patients 2 weeks-6 years of age. For patients 7 years and older, order Luteinizing Hormone, Serum (0070093).

86.
87.
88.
Ordering Recommendation:  

Evaluate patients with suspected immunodeficiency diseases, including severe combined immunodeficiency. Do not order for patients younger than 3 months unless clinical history of candidiasis is present.

89.
Ordering Recommendation:  

Primarily for research and to support attempts to understand the pathogenesis of immune, infectious, allergic, or inflammatory disorders. Do not order for patients younger than 3 months unless clinical history of candidiasis is present.

90.
Ordering Recommendation:  

Do not order for patients younger than 3 months unless clinical history of candidiasis is present.

91.
Ordering Recommendation:  

Primarily for research and to support attempts to understand the pathogenesis of immune, infectious, allergic, or inflammatory disorders.

92.
Ordering Recommendation:  

Primarily for evaluating T-cell function in patients with suspected cellular immune dysfunction, such as primary and secondary immunodeficiencies. Other uses include monitoring lymphocyte recovery and competence after hematopoietic stem cell transplantation and monitoring lymphocyte function during immunosuppressive therapy. Not a first-level test; order after Lymphocyte Proliferation, Mitogen Induced, by Flow Cytometry (3001321) has been performed.

93.
Ordering Recommendation:  

Primarily for evaluating recall antigen responses in patients with suspected cellular immune dysfunction, such as primary and secondary immunodeficiencies. Other uses include monitoring lymphocyte recovery and competence after hematopoietic stem cell transplantation and monitoring lymphocyte function during immunosuppressive therapy. Do not order for patients younger than 3 months unless clinical history of candidiasis is present.

94.
Ordering Recommendation:  

Primarily for evaluating lymphocyte function in patients with suspected cellular immune dysfunction, such as primary and secondary immunodeficiencies. Other uses include monitoring lymphocyte recovery and competence after hematopoietic stem cell transplantation and monitoring lymphocyte function during immunosuppressive therapy. Do not order for patients younger than 3 months unless clinical history of candidiasis is present.

95.
Ordering Recommendation:  

Primarily for evaluating lymphocyte function in patients with suspected cellular immune dysfunction, such as primary and secondary immunodeficiencies. Other uses include monitoring lymphocyte recovery and competence after hematopoietic stem cell transplantation and monitoring lymphocyte function during immunosuppressive therapy.

96.
Ordering Recommendation:  

Aids in clinical management of HIV-positive individuals.

97.
Ordering Recommendation:  

Absolute CD4 count is sufficient for routine HIV monitoring.

98.
Ordering Recommendation:  

Absolute CD4 count is sufficient for routine HIV monitoring.

99.
Ordering Recommendation:  

Absolute CD4 count is sufficient for routine HIV monitoring.

100.
Ordering Recommendation:  

Support the diagnosis of sarcoidosis.

101.
Ordering Recommendation:  

Evaluate for primary immunodeficiencies, including severe combined immunodeficiency, and monitor immune reconstitution following transplantation.

102.
Ordering Recommendation:  

Useful for assessing primary T-cell immunodeficiency disorders.

103.
Ordering Recommendation:  

Preferred lymphocyte subset panel for the investigation of primary immunodeficiency disorders.

104.
Ordering Recommendation:  

Monitor response to CD3 immunosuppressive therapy.

105.
Ordering Recommendation:  

Aid in the diagnosis of lymphocytic choriomeningitis (LCM) viral infection.

106.
Ordering Recommendation:  

Aid in the diagnosis of lymphocytic choriomeningitis (LCM) viral infection in CNS.

107.
Ordering Recommendation:  

Not recommended as a stand-alone test. Lymphocytic Choriomeningitis (LCM) Virus Antibodies, IgG & IgM (2001635) is preferred.

108.
Ordering Recommendation:  

Not recommended as a stand-alone test. Panel that includes lymphocytic choriomeningitis (LCM) virus IgG and IgM antibodies is preferred; refer to Lymphocytic Choriomeningitis (LCM) Virus Antibodies, IgG & IgM, CSF (2001628).

109.
Ordering Recommendation:  

Not recommended as a stand-alone test for identifying lymphocytic choriomeningitis (LCM) virus as pathology for meningitis. Lymphocytic Choriomeningitis (LCM) Virus Antibodies, IgG & IgM (2001635) is preferred.

110.
Ordering Recommendation:  

Not recommended as a stand-alone test. Lymphocytic Choriomeningitis (LCM) Virus Antibodies, IgG & IgM, CSF (2001628) is preferred.

111.
Ordering Recommendation:  

Aid in the diagnosis of aggressive large B-cell lymphoma with intermediate features between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL) and confirmation of suspected double-hit lymphoma. Reflex testing is available; refer to Aggressive B-Cell Lymphoma Reflex Panel by FISH, Tissue (3001495).
 

112.
113.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

114.
Ordering Recommendation:  

Aids in diagnosis of acute myelocytic leukemia or other leukemias, sarcoidosis, and infections such as tuberculosis.